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Abstract
Hypoxia‐inducible factor 1α (HIF‐1α) plays a critical role in the apoptotic process 
during cardiac ischaemia/reperfusion (I/R) injury. This study aimed to investigate 
whether post‐treatment with dexmedetomidine (DEX) could protect against I/R‐in‐
duced cardiac apoptosis in vivo and in vitro via regulating HIF‐1α signalling pathway. 
Rat myocardial I/R was induced by occluding the left anterior descending artery for 
30 minutes followed by 6‐hours reperfusion, and cardiomyocyte hypoxia/reoxy‐
genation (H/R) was induced by oxygen‐glucose deprivation for 6 hours followed by 
3‐hours reoxygenation. Dexmedetomidine administration at the beginning of reper‐
fusion or reoxygenation attenuated I/R‐induced myocardial injury or H/R‐induced 
cell death, alleviated mitochondrial dysfunction, reduced the number of apoptotic 
cardiomyocytes, inhibited the activation of HIF‐1α and modulated the expressions 
of apoptosis‐related proteins including BCL‐2, BAX, BNIP3, cleaved caspase‐3 and 
cleaved PARP. Conversely, the HIF‐1α prolyl hydroxylase‐2 inhibitor IOX2 partly 
blocked DEX‐mediated cardioprotection both in vivo and in vitro. Mechanistically, 
DEX down‐regulated HIF‐1α expression at the post‐transcriptional level and inhib‐
ited the transcriptional activation of the target gene BNIP3. Post‐treatment with 
DEX protects against cardiac I/R injury in vivo and H/R injury in vitro. These effects 
are, at least in part, mediated via the inhibition of cell apoptosis by targeting HIF‐1α 
signalling.
K E Y W O R D S
cardiac apoptosis, cardioprotection, dexmedetomidine, HIF‐1α, hypoxia/reoxygenation, 
ischaemia/reperfusion
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1  | INTRODUC TION
Although myocardial reperfusion is fundamental to the salvage of 
viable myocardium, the restoring coronary blood flow paradoxically 
leads to the death of cardiomyocytes—a phenomenon termed isch‐
aemia/reperfusion (I/R) injury.1,2 During procedures such as car‐
diopulmonary bypass and percutaneous coronary intervention, I/R 
injury is inevitable.3 In recent years, several ischaemic conditioning 
and pharmacological strategies to prevent I/R injury have been ex‐
amined; however, the translation from experimental findings to clin‐
ical application is extremely difficult.4,5
Apoptosis has been found to underlie myocardial I/R injury and 
infarction.6 Apoptotic process is initiated shortly after myocardial 
ischaemia and is greatly enhanced during reperfusion.7 Hypoxia‐in‐
ducible factor 1α (HIF‐1α) is a critical transcription factor and a key 
regulator in the process of hypoxia‐induced apoptosis.8 Depending 
on the severity of hypoxia, HIF‐1α either promotes cell survival by 
facilitating adaptation to low‐oxygen environments, or it induces 
apoptosis by activating pro‐apoptotic signalling.8
The α2‐adrenergic agonist dexmedetomidine (DEX) produces 
various beneficial effects in surgical patients, including sympatho‐
lytic, sedative, analgesic and opioid‐sparing effects.9 Our pre‐
vious study suggested that DEX use during cardiac surgery was 
correlated with a lower post‐operative mortality rate and fewer 
complications.10 Animal studies showed that DEX pre‐treatment 
attenuated myocardial I/R injury, in part, by inhibiting inflammatory 
responses.11,12
Compared with pre‐treatment, DEX administration at the onset 
of reperfusion (post‐treatment) is more applicable in clinical prac‐
tice. However, the underlying mechanism of DEX post‐treatment 
during cardiac I/R injury is unclear. Given the essential role of HIF‐1α 
in the I/R process, we hypothesized that post‐treatment with DEX 
could inhibit cardiac apoptosis after I/R in rats and after hypoxia/
reoxygenation (H/R) in cardiomyocytes by regulating the expression 
of HIF‐1α.
2  | MATERIAL S AND METHODS
2.1 | Animals and cells
Animal experimental protocol was approved by the Ethics Committee 
for Animal Experimentation of Soochow University (#2016‐064). 
The experimental procedures complied with the Guide for the Care 
and Use of Laboratory Animals (US National Institutes of Health). 
Adult male Sprague‐Dawley rats (8‐10 weeks old; 300‐350 g) and 
neonatal rats (1‐2 days old) were obtained from the Experimental 
Animal Centre of Soochow University, Suzhou, China. The rats re‐
ceived standard rodent food and water in a controlled environment 
(12‐hours light/dark cycle; room temperature, 22°C; 4‐5 rats per 
cage).
Neonatal rat cardiomyocyte cultures were prepared according 
to the method previously described.13,14 In brief, rat hearts were 
harvested and kept in a sterile phosphate‐buffered saline solution 
on ice. The ventricles were minced and digested five times with 
0.1% type II collagenase for 5 minutes each time at 37°C. The su‐
pernatants were collected in Dulbecco modified Eagle medium‐
F12 (DMEM‐F12) supplemented with 15% foetal bovine serum 
(FBS). Fibroblasts were separated by incubation for 2 hours and 
extraction of non‐adherent cells. Cells were seeded onto plates 
and cultured in media with 1% 5‐bromodeoxyuridine in a humidi‐
fied incubator containing 5% CO2 at 37°C. The culture media were 
replaced the next day, and the cells were used for experiments 
3‐4 days later.
2.2 | Drugs and reagents
Dexmedetomidine (Jiangsu Nhwa Pharmaceutical Co. Ltd.) in 
phosphate‐buffered saline (PBS); IOX2 (ApexBio) in 5% dimethyl 
sulfoxide (DMSO); type II collagenase, 5‐bromodeoxyuridine, so‐
dium pentobarbital, 2,3,5‐triphenyltetrazoliumchloride (Sigma); 
DMEM‐F12, non‐serum DMEM, FBS (Gibco); protease inhibitor 
cocktail (Roche); anti‐HIF‐1α, anti‐BCL‐2, anti‐BNIP3 (abcam); anti‐
caspase‐3, anti‐β‐tubulin (Cell Signalling Technology); anti‐BAX 
(Cell Signalling Technology and Ybscience); anti‐PARP‐1 (Santa Cruz 
Biotechnology); RT‐PCR primers (Sanggon); Trizol (Invitrogen); 5X 
All‐in‐One RT MasterMix, DNA fectin Plus, all vectors used in lucif‐
erase reporter gene assay (abm).
2.3 | I/R and H/R models
The myocardial I/R model was established as previously de‐
scribed.12,15 First, the rats were intraperitoneally anaesthetized with 
40 mg/kg sodium pentobarbital. The rats then underwent intuba‐
tion, ventilation (tidal volume, 5 mL/kg; 80 times/min), left thoracot‐
omy and left anterior descending (LAD) artery ligation ~2 mm below 
the left auricle. The LAD occlusion was maintained for 30 minutes of 
ischaemia, and then, the ligature was released for reperfusion of 2, 
6 and 24 hours. Model establishment was confirmed by S‐T segment 
elevation and myocardial blanching. A 24G intravenous catheter was 
inserted into the right jugular vein for DEX infusion. Throughout the 
procedure, the body temperature of the rats was maintained at 37°C 
by using a heating pad and a rectal thermometer. After the experi‐
ment, the animals were sacrificed after intraperitoneal pentobarbital 
100 mg/kg.
To establish the in vitro H/R model, the neonatal rat cardiomy‐
ocytes were incubated in an anaerobic Plexiglas chamber (Billups‐
Rothenberg) containing 95% N2 and 5% CO2 at 37°C. Prior to 
hypoxia, the culture media were replaced with non‐glucose and 
non‐serum DMEM. For reoxygenation, the cells were transferred to 
FBS‐containing DMEM under normal conditions.
2.4 | Experimental protocols
An investigator who was not involved in the subsequent study per‐
formed randomization using a computer‐generated table and pre‐
pared the study solutions. The investigators who carried out the 
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following experiments and data analyses were blinded to the group 
allocation. The experimental protocols are presented in Figure 1.
1. To evaluate the possible cytotoxicity of DEX, cell viability was 
measured after treatments with 0.1, 1, 10 and 50 μM DEX 
for 24 hours in normal conditions.
2. To observe the time course of cell survival during H/R, cell viabil‐
ity was assessed after exposure to hypoxia for 3, 6 and 12 hours 
followed by reoxygenation for 3, 6, 12 and 24 hours.
3. Cell viability and cytotoxicity were measured after 0.1, 1, and 
10 μM DEX treatments in cells subjected to H/R.
4. DEX 1 μM was added to the culture media at the beginning of 
reoxygenation. The apoptosis rate and the expression of HIF‐1α 
and BAX were determined.
5. To explore the role of HIF‐1α in the cardioprotective effects of 
DEX, we tested the effects of 50 μM IOX2, a selective and po‐
tent inhibitor of HIF‐1α prolyl hydroxylase‐2 (PHD2),16‐18 on cell 
viability, the mitochondrial apoptotic pathway, and the expres‐
sion of HIF‐1α and the apoptosis‐related proteins including B‐cell 
lymphoma‐2 (BCL‐2), Bcl‐2 associated X protein (BAX), Bcl‐2/
adenovirus E1B 19kD‐interacting protein 3 (BNIP3), cleaved cas‐
pase‐3 and poly ADP‐ribose polymerase 1 (PARP1).
6. To further investigate the underlying mechanisms, we evaluated 
the HIF‐1α and BNIP3 mRNA levels and the transcriptional activa‐
tion of the BNIP3 promoter by HIF‐1α in cardiomyocytes.
7. In rats, HIF‐1α protein levels were measured at 2, 6 and 24 hours 
of reperfusion to analyse the time course of HIF‐1α expression 
during I/R.
8. To examine the effects of DEX on myocardial injury, HIF‐1α and 
apoptosis, DEX (6 μg/kg/h × 10 minutes + 0.7 μg/kg/h × 15 min‐
utes) was administered intravenously at the beginning of reperfu‐
sion. Serum cardiac troponin I (cTnI), myocardial apoptosis index, 
infract size, and the expression of HIF‐1α and apoptosis‐related 
proteins were analysed. IOX2 25 mg/kg was injected intraperi‐
toneally prior to DEX administration.16 The sham rats underwent 
chest open without LAD ligation and received normal saline infu‐
sion. The doses of DEX 12,19 and IOX216,17 use in this study were 
based on our preliminary experiments and previous studies.
F I G U R E  1   Experimental protocols. A, Part I: neonatal rat cardiomyocytes were subjected to hypoxia/reoxygenation. B, Part II: cells 
were transfected with reporter plasmids and luciferase activity was assessed. C, Part III: rats underwent myocardial ischaemia/reperfusion. 
OGD, oxygen‐glucose deprivation; DEX, dexmedetomidine; LAD, left anterior descending; ∆Ψm, mitochondrial membrane potential; ECG, 
electrocardiography; cTnI, serum cardiac troponin I; and HR, heart rate
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2.5 | Electrocardiography and blood analysis
Throughout the animal experiment, electrocardiographic (ECG) 
changes were monitored using a biological signal‐processing sys‐
tem (MedLab). Heart rate was recorded at the baseline, at 15 and 
30 minutes of ischaemia and at 15, 30 and 60 minutes of reperfu‐
sion. At 6 hours of reperfusion, blood samples were taken from the 
abdominal aorta and the pH, partial pressures of oxygen (PaO2) 
and carbon dioxide (PaCO2), arterial oxygen saturation (SaO2), 
haemoglobin (Hb), haematocrit (Hct), Na+, K+, Ca2+, Cl−, HCO3
− 
and base excess (BE) were measured using a blood‐gas analyzer 
(Radiometer).
2.6 | Enzyme‐linked immunosorbent assay
Serum cTnI levels were quantified using a commercial kit (Life 
Diagnostics) according to the manufacturer's instructions. We meas‐
ured the absorbance values at 450 nm by using the SpectraMax190 
plate reader (MD) and determined the sample concentrations by 
using a standard curve.
2.7 | TUNEL assay
Myocardial apoptosis was detected by TUNEL assays (Roche) ac‐
cording to the manufacturer's instructions. Myocardial tissue slices 
were counterstained with 4′,6‐diamidino‐2‐phenylindole (DAPI). The 
total myocardial cell nuclei and TUNEL‐positive nuclei were counted 
in four random and non‐overlapping fields per slice. The apoptosis 
index was defined as the ratio of TUNEL‐positive cells to the total 
number of cells. The cells were imaged using the DM2500 fluores‐
cence microscope (Leica), and the images were analysed with ImageJ 
(NIH).
2.8 | Infarct size
Following I/R, we re‐occluded the LAD and injected 2% Evans blue 
dye into the aorta. The heart was excised, frozen and transversely 
sectioned into five 2‐mm‐thick slices. Next, all slices were stained 
using 1% 2,3,5‐triphenyltetrazoliumchloride at 37°C for 30 minutes 
and digitally photographed. The images were analysed with ImageJ. 
The infarct area (IA) was expressed as a percentage of the total area 
at risk (AAR): IA/AAR × 100%.
2.9 | Cell viability and lactate 
dehydrogenase activity
Cell viability was evaluated by using the Cell Counting Kit‐8 (CCK‐8) 
assay (Beyotime), and cytotoxicity was quantified using the lactate 
dehydrogenase (LDH) activity assay (Beyotime) according to the 
manufacturer's instructions. We measured the absorbance values 
at 490 nm by using the SpectraMax190 plate reader. Three techni‐
cal replicates were tested, and the average value was calculated for 
each sample.
2.10 | Flow cytometry
The cell apoptosis rate was measured by using an annexin V‐fluores‐
cein isothiocyanate/propidium iodide apoptosis kit (BD Biosciences) 
according to the manufacturer's instructions. We analysed the cel‐
lular fluorescence with the FACSCalibur™ flow cytometer (BD 
Biosciences). Three technical replicates were applied for each sample.
2.11 | Mitochondrial membrane potential
Mitochondrial membrane potential (∆Ψm) changes were detected 
by JC‐1 staining (Beyotime) according to the manufacturer's instruc‐
tions. In healthy cells with polarized inner membranes, JC‐1 accu‐
mulates as aggregates, showing red fluorescence. In apoptotic cells 
with ∆Ψm dissipation, cytosolic JC‐1 monomers show green fluores‐
cence. The ratio of JC‐1 monomers to aggregates was calculated in 
four random and non‐overlapping fields per slice using the DM2500 
fluorescence microscope and analysed with ImageJ.
2.12 | Immunoblotting
Cardiac tissues and cardiomyocytes were homogenized in lysis buffer 
supplemented with the cOmplete™ Protease Inhibitor Cocktail. Next, 
we separated the proteins thus obtained using sodium dodecyl sul‐
phate‐polyacrylamide gel electrophoresis on 10%‐12% gels. We trans‐
ferred the separated proteins to nitrocellulose membranes, which 
were then blocked and incubated overnight at 4°C with the follow‐
ing primary antibodies: anti‐HIF‐1α, 1:500 (abcam); anti‐BAX, 1:1000 
(Cell Signalling Technology); anti‐BCL‐2, 1:500 (abcam); anti‐BNIP3, 
1:1000 (abcam); anti‐caspase‐3, 1:1000 (Cell Signalling Technology); 
anti‐PARP1, 1:500 (Santa Cruz Technology); and anti‐β‐tubulin, 
1:1000 (Cell Signalling Technology). After this, the membranes were 
incubated for 1 hour at room temperature with rat anti‐mouse or goat 
anti‐rabbit secondary antibodies. Three replicates were tested for 
each sample. Finally, we visualized the blots by using chemilumines‐
cence and a luminescent imaging workstation (Tanon 5200).
2.13 | Immunofluorescence staining
Cells grown on coverslips were fixed with 4% paraformaldehyde, 
permeabilized with 0.3% Triton X‐100, blocked and incubated over‐
night at 4°C with the following primary antibodies: anti‐HIF‐1α, 
1:200 (abcam); anti‐BAX, 1:200 (Ybscience); and anti‐α‐SMA, 1:200 
(abcam). This was followed by incubation with the appropriate sec‐
ondary antibodies for 1 hour at room temperature. We counter‐
stained the cell nuclei with DAPI and observed and analysed the 
stained cells using the DM2500 fluorescence microscope and ImageJ.
2.14 | Quantitative reverse transcription 
polymerase chain reaction assay
We extracted total RNA with Trizol, and reverse tran‐
scribed 1 µg of the extracted total RNA using the 5X 
854  |     PENG Et al.
All‐in‐One RT MasterMix. Real‐time quantitative reverse tran‐
scription polymerase chain reaction (RT‐PCR) assays were 
performed with the CFX96™ Touch system (Bio‐Rad) and the fol‐
lowing specific primers: HIF‐1α, 5′‐TGAGGACACGAGCTGCCTCT‐3′ 
(forward) and 5′‐GTGTCATCGCTGCCGAAGT‐3′ (reverse); 
BNIP3, 5′‐GCTACCTCTCAGTGGTCACTTCC‐3′ (forward) 
and 5′‐TGCTGAAGTGCAGTTCTACCCA‐3′ (reverse); and 
β‐tubulin, 5′‐TGTCACCAACTGGGACGATA‐3′ (forward) and 5′‐
GGGGTGTTGAAGGTCTCAAA‐3′ (reverse). Three technical repli‐
cates were applied for each sample. We assessed gene abundance 
using the 2−ΔΔCt method.
2.15 | Transient transfections and dual luciferase 
reporter gene assay
First, neonatal rat cardiomyocytes were cotransfected with a re‐
porter plasmid (pLenti‐miniCMV‐RenLuc‐BNIP3 promoter‐Luc‐
SV40‐GFP‐2A‐Puro vector) containing the BNIP3 promoter and the 
Renilla luciferase or a BNIP3 promoter mutation vector, and a HIF‐1α 
lentiviral vector (pLenti‐GIII‐CMV‐GFP‐2A‐Puro) for overexpression 
or a blank vector (2 µg for each vector) using DNA fectin Plus for 
24 hours. The cells were then harvested for the luciferase activity 
analyses. Next, neonatal rat cardiomyocytes were transfected with 
2 µg reporter plasmid for 24 hours, followed by incubation under 
either normal or H/R conditions with or without DEX.
At the end of the transfection, we observed the cells using the 
DM2500 fluorescence microscope. To measure the luciferase activ‐
ity, we used the Firefly & Renilla Luciferase Single Tube Assay Kit 
(Biotium) and the GloMax® 96 Microplate Luminometer (Promega). 
We normalized the firefly luciferase luminescence activity to the 
Renilla luciferase activity.
2.16 | Statistical analysis
Data are expressed as mean ± standard error of the mean (SEM). 
Within‐group differences were evaluated using one‐way or two‐way 
analysis of variance (ANOVA) followed by Dunnett test. GraphPad 
Prism (version 7.0) was used for all statistical analyses. P < .05 indi‐
cated statistically significant differences.
3  | RESULTS
3.1 | DEX alleviated H/R injury, inhibited apoptosis 
and reduced HIF‐1α and BAX expression in neonatal 
rat cardiomyocytes
The purified neonatal rat cardiomyocytes are shown in Figure 2A. 
Incubation with DEX 0.1‐10 µM did not significantly change cell via‐
bility, but DEX 50 µM resulted in decreased cell viability (Figure 2B). 
The maximum tolerated concentration of DEX in clinical use is 
15 ng/mL (equivalent to 75 nM).14,20 Thus, DEX is not cytotoxic 
to cultured neonatal rat cardiomyocytes at the clinically relevant 
concentration.
Hypoxia/reoxygenation exposure significantly decreased cell vi‐
ability (Figure 2C). After analysing the time course of cell survival, we 
selected 6‐hours hypoxia followed by 3‐hours reoxygenation, which 
led to a 40% decrease in cell viability, for the subsequent experi‐
ments. Next, the effects of 0.1, 1 and 10 µM of DEX were evaluated. 
We found that 1 µM DEX led to the highest cell viability (Figure 2D) 
and lowest LDH release (Figure 2E).
Hypoxia/reoxygenation markedly increased the apoptosis rate, 
whereas post‐treatment with 1 µM DEX reduced the apoptosis rate 
(Figure 2F). H/R exposure also resulted in the subcellular co‐localiza‐
tion and high expression of HIF‐1α and BAX, which was effectively 
attenuated by DEX (Figure 2G).
3.2 | DEX protected cardiomyocytes against H/R‐
induced apoptosis by targeting HIF‐1α
IOX2, a potent and selective PHD2 inhibitor, stabilized HIF‐1α pro‐
tein expression without significant adverse effects on cell viability or 
apoptosis‐related proteins, including BNIP3 and cleaved caspase‐3 
(Figure 3A,B). However, IOX2 treatment significantly abolished the 
improvement of cell viability by DEX (Figure 3B).
To investigate the effects of DEX on mitochondrial function 
during H/R, we detected changes in ∆Ψm by using JC‐1 staining. 
H/R exposure resulted in remarkable △Ψm dissipation in cells, as 
indicated by the increased ratio of green/red immunofluorescence 
intensity. Dexmedetomidine treatment attenuated H/R‐induced 
△Ψm dissipation, and this effect was partly blocked by IOX2 
(Figure 3C). Furthermore, DEX treatment reduced HIF‐1α, BAX, 
BNIP3, cleaved caspase‐3 and cleaved PARP‐1 protein levels and 
restored BCL‐2 protein expression and the ratio of BCL‐2 to BAX 
in cells subjected to H/R, which was partially reversed by IOX2 
(Figure 3D).
3.3 | DEX blocked HIF‐1α‐induced transcriptional 
activation of BNIP3 expression in neonatal rat 
cardiomyocytes
Exposure of neonatal rat cardiomyocytes to H/R markedly elevated 
the mRNA expression of both HIF‐1α and its target gene BNIP3. 
However, DEX treatment only reduced the levels of BNIP3 mRNA, 
but not HIF‐1α mRNA (Figure 4A). The amplification, melt peak and 
melt curve of products of RT‐PCR reactions confirmed the reliability 
of the results (Figure 4B).
At the end of the transfection, high green fluorescence indicated 
that the cells were effectively transfected (Figure 4C). The cells with 
HIF‐1α overexpression showed significantly higher luciferase activ‐
ity than the control or blank vector groups, while the luciferase ac‐
tivity was reduced in the BNIP3 promoter mutant group (Figure 4D). 
Moreover, the luciferase reporter gene assay showed that DEX 
treatment reduced the luciferase‐elicited fluorescence in cells sub‐
jected to H/R, which was partly reversed by IOX2 (Figure 4E). These 
results confirmed that DEX blocked the HIF‐1α‐induced transcrip‐
tional activation of BNIP3 expression.
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F I G U R E  2   DEX post‐treatment alleviated H/R‐induced injury, inhibited apoptosis and reduced HIF‐1α and BAX expression in neonatal 
rat cardiomyocytes. A, Immunostaining of α‐SMA showing purified cardiomyocytes. Scale bars: 50 (left and middle rows) and 200 µm (right 
row). B, CCK‐8 assay showing that DEX 0.1‐10 µM had no cytotoxicity. C, CCK‐8 assay showing significant decreases in cell viability after 
different durations of H/R (eg H3R3 indicates 3 hours of hypoxia followed by 3‐hours of reoxygenation). D, CCK‐8 assay showing the effects 
of DEX post‐treatment on cell viability. E, LDH assay showing the effects of DEX on cytotoxicity. F, Flow cytometric assessment of annexin 
V‐FITC/PI staining showing that DEX reduced apoptotic cells. G, Immunofluorescence showing that DEX inhibited the expression of HIF‐1α 
(green) and BAX (red). Scale bar: 30 µm. n = 6. **P < .01 vs control; ##P < .01 vs H/R; $P < .05, $$P < .01 for the comparisons shown
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3.4 | DEX alleviated myocardial apoptosis and I/R 
injury in rats
The I/R procedures resulted in remarkable S‐T segment elevation 
during ischaemia and arrhythmias during reperfusion (Figure 5A). 
Dexmedetomidine did not significantly change S‐T segment eleva‐
tion or the subsequent arrhythmias. Nine animals died prior to the 
experimental end‐point due to blood loss, myocardial infarction or 
severe arrhythmias (two in I/R group, two in I/R + IOX2 group, two in 
IR + DEX + IOX2 group, one in I/R + DEX group, one in IR + DEX + ve‐
hicle group and one in Sham group).
During I/R, the HIF‐1α protein level peaked at 6 hours after 
reperfusion (Figure 5B). We selected 30 minutes ischaemia followed 
by 6‐hours reperfusion for the subsequent experiments. The I/R rats 
showed significant myocardial damage, as evidenced by increased 
serum cTnI levels, which was effectively reduced by DEX (Figure 5C). 
TUNEL assays were performed to assess DNA fragmentation in 
apoptotic cells. Significantly, fewer TUNEL‐positive cells were ob‐
served after DEX treatment, indicating that DEX ameliorated I/R‐in‐
duced DNA fragmentation (Figure 5D). However, these protective 
effects of DEX were abolished by IOX2.
During I/R, the heart rate was recorded at the baseline, 15 and 
30 minutes after ischaemia, and 15, 30 and 60 minutes after reper‐
fusion. The heart rate decreased slightly but not significantly after 
DEX administration (Table S1).
3.5 | DEX protected against I/R‐induced myocardial 
infarction and apoptosis by targeting HIF‐1α
Myocardial infarct size was significantly larger in the I/R group 
rats than in the sham group rats, and IOX2 treatment did not 
further increase the infarct size (Figure 6A). Dexmedetomidine 
treatment notably reduced infarct size, and this effect was partly 
diminished by IOX2. Dexmedetomidine also reduced the levels of 
F I G U R E  3   IOX2 abolished the effects of DEX post‐treatment on HIF‐1α, apoptosis‐related proteins and mitochondrial membrane 
potential in neonatal rat cardiomyocytes. A, Immunoblotting showing that IOX2 stabilized HIF‐1α protein expression without affecting 
BNIP3 and cleaved caspase‐3 protein levels. B, CCK‐8 assay showing no significant cytotoxicity associated with IOX2 and that the effects of 
DEX on cell viability were reversed by IOX2. C, Immunofluorescent staining of JC‐1 showing that DEX restored the ratio of JC‐1 aggregates 
in normal mitochondria (red) to JC‐1 monomers in dysfunctional mitochondria (green), which was partly blocked by IOX2. Scale bar: 30 µm. 
D, Immunoblotting showing that IOX2 partly reversed the effects of DEX treatment on HIF‐1α, BCL‐2, BAX, BNIP3, cleaved caspase‐3 and 
cleaved PARP‐1 protein levels. n = 6. **P < .01 vs control; #P < .05, ##P < .01 vs H/R; $P < .05, $$P < .01 for the comparisons shown
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the HIF‐1α, BAX, BNIP3, cleaved caspase‐3 and cleaved PARP‐1 
proteins and increased the BCL‐2 protein level and the ratio of 
BCL‐2 to BAX, while IOX2 treatment partly abolished these ef‐
fects (Figure 6B).
Blood analyses showed that all parameters including pH, PaO2, 
PaCO2, SaO2, Hb, Hct, Na
+, K+, Ca2+, Cl−, HCO3
− and BE were within 
the normal range at 6 hours of reperfusion. Compared with the sham 
group, the I/R group rats showed decreases in PaCO2, HCO3
− and 
BE levels, but the differences among the groups were not significant 
(Table S2).
4  | DISCUSSION
This study demonstrates that DEX post‐treatment conferred car‐
dioprotection on rat hearts and cardiomyocytes, as evidenced by 
improved serum cTnI levels (or cell viability and LDH release), alle‐
viated mitochondrial dysfunction, reduced DNA fragmentation (or 
apoptosis rate), decreased myocardial infarct size and down‐regu‐
lated protein expressions of apoptosis‐related genes. These pro‐
tective effects of DEX were partly abolished by inhibiting HIF‐1α 
degradation with IOX2. Furthermore, this is the first study to dem‐
onstrate that DEX inhibits the HIF‐1α‐induced activation of the tar‐
get gene BNIP3 at the post‐transcriptional level.
HIF‐1α, a master regulator of the hypoxia response, is induced 
by hypoxia and regulates the expression of a large range of target 
genes. Under normal conditions, HIF‐1α protein is hydroxylated by 
PHDs, ubiquitinated and degraded by 26S proteasomes.21 During 
hypoxia, the hydroxylation process is blocked, and HIF‐1α accumu‐
lates to exert its transcriptional activities.22 The severity of hypoxia 
determines whether cells adapt to hypoxic stress or become apop‐
totic.8 Some studies have suggested that HIF‐1α is a fundamental 
element of the intrinsic survival signalling to protect against I/R 
injury.23‐25 Specifically, they showed that I/R‐induced myocardial 
injury is alleviated by interventions that up‐regulate HIF‐1α expres‐
sion. However, high HIF‐1α expression can also initiate a sequence of 
F I G U R E  4   DEX inhibited HIF‐1α‐induced transcriptional activation of BNIP3 expression. A, Quantitative RT‐PCR showing that 
DEX reduced BNIP3 mRNA, but not HIF‐1α mRNA. B, Amplification, melt peak and melt curve of three genes in RT‐PCR. C, High green 
fluorescence showing that the cells were effectively transfected. Scale bars: 100 (left row) and 50 µm (right row). D, Dual luciferase reporter 
gene assay showing that HIF‐1α DNA led to significantly high luciferase activity, which was reduced after transfection with the BNIP3 
promoter mutation vector. E, Dual luciferase reporter gene assay showing that DEX blocked the activity of the BNIP3 promoter in the 
presence of hypoxia‐response elements, which was reversed by IOX2. n = 6. **P < .01 vs control (or BNIP3promoter); #P < .05, ##P < .01 vs 
H/R; $$P < .01 for the comparisons shown
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events that lead to apoptotic cell death.8 Under this condition, treat‐
ments that inhibited the HIF‐1α activity reduced I/R and H/R injuries 
in rat hearts and cardiomyocytes, respectively,26‐28 which is in line 
with our results. A recent study also revealed that miR‐210 reduces 
the renal tubular cell apoptosis that occurs in response to hypoxia 
by suppressing HIF‐1α pathway activation.29 The inconsistency be‐
tween the pro‐survival and the pro‐apoptotic effects of HIF‐1α may 
be attributable to differences in cell environments and the severity 
of hypoxia.
The protective effects of DEX against myocardial I/R injury 
have been observed in various animal models. In isolated rat 
hearts, DEX administration before ischaemia reduced coronary 
blood flow but improved infarct size, and this effect was reversed 
by yohimbine (an α‐2 adrenergic antagonist).30 In another study, 
DEX pre‐treatment activated Erk 1/2, Akt and eNOS, improved 
myocardial function and decreased infarct size after myocardial 
I/R both in vivo and ex vivo.19 In grave scalding rats, DEX pro‐
tected against myocardial apoptosis.31 In pigs, intracoronary DEX 
infusion reduced reperfusion‐induced ventricular arrhythmias and 
suppressed plasma norepinephrine concentrations, indicating that 
DEX provided cardioprotection via a direct action on the myocar‐
dium.32 Of note, DEX pre‐treatment was found to protect isolated 
F I G U R E  5   DEX alleviated myocardial I/R injury and apoptosis in rats. A, ECG patterns in normal conditions, ischaemia and reperfusion 
phase. B, Immunoblotting showing the time course of HIF‐1α protein expression. C, ELISA showing that DEX post‐treatment reduced the 
I/R‐induced increase in serum cTnI, which was reversed by IOX2. D, TUNEL assay showing that DEX reduced myocardial apoptosis after 
I/R, which was diminished by IOX2. Scale bar: 200 µm. n = 6. **P < .01 vs sham; #P < .05, ##P < .01 vs I/R; $P < .05, $$P < .01 for the 
comparisons shown
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rat hearts and adult rat cardiomyocytes via the activation of eNOS/
NO signalling, but this effect required the interaction of DEX‐pre‐
treated endothelial cells.33 However, our findings on cardiomyo‐
cytes suggest that DEX may directly act on the cells. Recently, our 
studies showed that DEX pre‐treatment attenuated I/R‐induced 
cardiac injury by inhibiting inflammation.11‐13 In addition to its car‐
dioprotective benefits, DEX has been found to attenuate I/R injury 
in other vital organs, including the brain, liver, kidney, lungs and 
spinal cord.34‐38
Few studies have investigated the effects of DEX post‐treat‐
ment; however, administration at the onset of reperfusion is more 
applicable in clinical practice. A previous study failed to show the 
protective effect of DEX post‐treatment against myocardial in‐
jury.39 However, isolated rat hearts were used in that study, and 
only myocardial infarct size was measured and the authors were 
not able to show any possible mechanism. Another study reported 
that the post‐ischaemic use of DEX protected the heart against I/R 
through PI3K/Akt‐dependent signalling, but this study did not inves‐
tigate the mechanism at the cellular level.40 In the mouse brain, DEX 
post‐treatment attenuated I/R injury by inhibiting neuronal autoph‐
agy.41 Based on our current findings, DEX may be used for cardi‐
oprotection at the initiation of reperfusion at the clinical settings.
This study has several limitations. First, we did not conduct car‐
diac‐function tests to investigate the beneficial role of DEX in rats. 
Nevertheless, our recent study has shown that DEX improved car‐
diac function in isolated hearts during I/R injury.11 Next, no survival 
benefit of DEX was shown in our animals. A much larger sample size 
may be required to detect a difference in survival outcomes. Last, 
it may still be difficult to extrapolate these animal data to humans 
due to the species differences. Therefore, more clinical studies are 
needed to confirm DEX's cardioprotection.
In conclusion, the protective effects of DEX against rat myo‐
cardial I/R and cardiomyocyte H/R are mediated, at least in part, 
by the inhibition of apoptosis via the regulation of HIF‐1α signal‐
ling (Figure 7). These findings reveal a potential cardioprotective 
mechanism of DEX, which provides a basis for therapeutic strat‐
egies to improve outcomes in patients at risk for myocardial I/R 
injury.
F I G U R E  6   IOX2 diminished the effects of DEX post‐treatment on infarct size, HIF‐1α and apoptosis‐related proteins in rats. A, Evans 
blue/TTC staining showing that DEX reduced myocardial infarct size after I/R, which was abolished by IOX2. B, Immunoblotting showing 
that IOX2 blocked the effects of DEX on HIF‐1α, BAX, BCL‐2, BNIP3, cleaved caspase‐3 and cleaved PARP‐1 proteins. n = 6. *P < .05, 
**P < .01 vs sham; #P < .05, ##P < .01 vs I/R; $P < .05, $$P < .01 for the comparisons shown
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